Theravance Biopharma, Inc. (TBPH) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Reported outsized returns ⢠Receivables concentration TBPH shows strong liquidity and very high reported returns with modest multiples, but large receivables, unusual margin/reporting anomalies, tax liabilities and recent cash volatility warrant deeper disclosure review.
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Critical support ⢠Gap-driven risk Support Level: $13.50â$14.00 Resistance Level: $16.20; next $19.00 TBPH rallied ~18% last month to $16.02, showing short-term upside momentum while holding above $13.50â$14.00 support and needing a break above ~$16.20 to retest pre-drop highs near $19.00.
Sentiment & News
Key News Insights: ⢠Phase 3 failure ⢠Strategic review ⢠Investor investigations Theravance's Phase 3 ampreloxetine failure triggered a ~26% stock drop, prompted organizational restructuring and a Strategic Review amid investor lawsuits, while the company signals roughly $400M cash, cost cuts and possible asset-sale options.
AI Summary
TBPH has effectively shifted from a binary, developmentâled biotech to a singleâproduct, cashâgeneration story where valuation now hinges on YUPELRI profitability, milestone/royalty cash receipts, and disciplined redeployment rather than pipeline upsideâso prioritize monitoring actual milestone cash inflows, YUPELRI net sales trends, and realized restructuring savings as the primary drivers of nearâterm value. The key risk is concentrated revenue and contingent milestone timing plus active securities litigation, any of which could quickly erode runway or force dilutive/defensive transactions.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |